DehydraTECH-CBD for Diabetes
Diabetes / Metabolic Syndrome
Pre-clinicalActive (Research)
Key Facts
Indication
Diabetes / Metabolic Syndrome
Phase
Pre-clinical
Status
Active (Research)
Company
About Lexaria Bioscience
Lexaria Bioscience is a pre-revenue, public biotech company commercializing its DehydraTECH™ drug delivery platform. Its core technology aims to improve the oral delivery of fat-soluble compounds, with demonstrated applications in cannabinoids and pharmaceuticals for conditions like hypertension and diabetes. The company's strategy relies on out-licensing its patented platform to generate future royalty and fee-based revenue, avoiding the high costs of drug development and commercialization. With a low market valuation and trading near its 52-week low, Lexaria represents a high-risk, high-potential investment in drug delivery innovation.
View full company profile